Previous 10 | Next 10 |
Recro Pharma (NASDAQ: REPH ): Q3 GAAP EPS of -$0.19 misses by $0.03 . More news on: Recro Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100 Million FDA Grants Appeal for IV Meloxicam New Drug Application Company Remains on Tr...
MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report third quarter financial results on Friday, November 8, 2019. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on ...
MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that its board of directors has approved the planned spin-of...
Recro Pharma ( REPH ) recently announced that the FDA has granted Recro's appeal of the Complete Response Letter "CRL" for the company's IV Meloxicam product. In the press release, the company cited the FDA's statement that the appeal was granted due to "specific to the request… that th...
Recro Pharma ( REPH +11% ) is up on more than double normal volume in response to the FDA granting its appeal of the Complete Response Letter (CRL) it received in March related to its marketing application for IV meloxicam. More news on: Recro Pharma, Inc., Healthcare stocks news, St...
Received Positive Response from FDA Regarding IV Meloxicam Formal Dispute Resolution Request Company Remains on Track to Execute Spin Out of Acute Care Business Segment During the Fourth Quarter of 2019 MALVERN, Pa., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH...
Avid Bioservices (NASDAQ: CDMO ) initiated with Overweight rating and $8 (60% upside) price target at Stephens. Shares up a fraction premarket. More news on: Avid Bioservices, Inc., NGM Biopharmaceuticals, Inc., Recro Pharma, Inc., Healthcare stocks news, Stocks on the move, , Read mor...
Recro Pharma ( REPH ) investors should be pleased with the company's performance since the IV meloxicam CRL . Recro's efforts to cut OpEx and grow their CDMO segment took the share price from a 52-week low in March to a 52-week high a couple of weeks ago. REPH Daily Chart (Source: Trendspi...
Recro Pharma, Inc. (REPH) Q2 2019 Earnings Conference Call August 8, 2019 08:00 AM ET Company Participants Claudia Styslinger - IR Geraldine Henwood - President & CEO Ryan Lake - CFO Conference Call Participants Leland Gershell - Oppenheimer & Co. Michael Ingerman...
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...